In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is ...

In October, lenacapavir manufacturer, Gilead, announced a deal that allows six manufacturers to produce generic versions of ...

The stock's fall snapped an eight-day winning streak.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...

The shot was 100% effective in preventing HIV infections in a study of women, and results published Wednesday show it worked ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis Tuesday said they have entered into an option and license agreement to discover and ...

Gilead (GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover and develop an ...